tiprankstipranks
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC

Oric Pharmaceuticals Stock Analysis & Ratings

ORIC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.62 - $26.70
Previous Close$4.5
Volume31.15K
Average Volume (3M)630.65K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-2.0
Beta2.20
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ORIC FAQ

What was Oric Pharmaceuticals’s price range in the past 12 months?
Oric Pharmaceuticals lowest stock price was $2.62 and its highest was $26.70 in the past 12 months.
    What is Oric Pharmaceuticals’s market cap?
    Currently, no data Available
    What is Oric Pharmaceuticals’s price target?
    The average price target for Oric Pharmaceuticals is $9.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $9.00 ,the lowest forecast is $9.00. The average price target represents 100.89% Increase from the current price of $4.48.
      What do analysts say about Oric Pharmaceuticals?
      Oric Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
        When is Oric Pharmaceuticals’s upcoming earnings report date?
        Oric Pharmaceuticals’s upcoming earnings report date is Aug 10, 2022 which is in 41 days.
          How were Oric Pharmaceuticals’s earnings last quarter?
          Oric Pharmaceuticals released its earnings results on May 09, 2022. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.568 by -$0.022.
            Is Oric Pharmaceuticals overvalued?
            According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Oric Pharmaceuticals pay dividends?
              Oric Pharmaceuticals does not currently pay dividends.
              What is Oric Pharmaceuticals’s EPS estimate?
              Oric Pharmaceuticals’s EPS estimate is -$0.6.
                How many shares outstanding does Oric Pharmaceuticals have?
                Oric Pharmaceuticals has 39,478,210 shares outstanding.
                  What happened to Oric Pharmaceuticals’s price movement after its last earnings report?
                  Oric Pharmaceuticals reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.568. Following the earnings report the stock price went up 5.185%.
                    Which hedge fund is a major shareholder of Oric Pharmaceuticals?
                    Among the largest hedge funds holding Oric Pharmaceuticals’s share is Invus Financial Advisors, LLC. It holds Oric Pharmaceuticals’s shares valued at 5M.

                      ---

                      Oric Pharmaceuticals Stock Analysis

                      The Oric Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Oric Pharmaceuticals

                      ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Lyra Therapeutics
                      Inari Medical
                      Legend Biotech
                      Revolution Medicines
                      Passage Bio

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis